



## **Akerro Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference**

October 11, 2022

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Akerro Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the H.C. Wainwright 6<sup>th</sup> Annual NASH Virtual Investor Conference on Monday, October 17, 2022, at 12:00 p.m. E.T.

A webcast of the Company presentation will be available through the investor relations section of the Company's website at [www.akerotx.com](http://www.akerotx.com). Following the webcast, an archived replay will be available on the Company's website.

### **About Akerro Therapeutics**

Akerro Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akerro's lead product candidate, efruxifermin (EFX), is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX is designed to offer convenient once-weekly subcutaneous dosing. The consistency and magnitude of observed effects position EFX to be a potentially best-in-class medicine, if approved, for treatment of NASH. EFX is currently being evaluated in two Phase 2b clinical trials: the HARMONY study in patients with pre-cirrhotic NASH (F2-F3 fibrosis), and the SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis, compensated). EFX is also being evaluated in an expansion cohort of the SYMMETRY study, comparing the safety and tolerability of EFX to placebo when added to an existing GLP-1 receptor agonist in patients with pre-cirrhotic NASH (F1-F3 fibrosis) and Type 2 diabetes.

### **Investor Contact:**

Christina Tartaglia  
Stern Investor Relations, Inc.  
212.362.1200  
[christina.tartaglia@sternir.com](mailto:christina.tartaglia@sternir.com)

### **Media Contact:**

650.487.6488  
[media@akerotx.com](mailto:media@akerotx.com)